Last updated on September 2018

Venetoclax Registry


Brief description of study

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax

Detailed Study Description

The aim of this study is to document all patients with AML who are treated with the BCL2 inhibitor Venetoclax outside a clinical trial in all hospitals participating in this registry study in a standardised manner. Data is collected retrospectively and multi-centric. It is neither a therapy study nor is the therapy influenced by this study.

  1. Systematic and uniform collection and documentation of all patients treated with the BCL2 inhibitor Venetoclax.
  2. Collection and integrative analysis of clinical data of included patients.
  3. Mutation analysis of available patient samples and correlation with clinical parameters.

Clinical Study Identifier: NCT03662724

Contact Investigators or Research Sites near you

Start Over

Michael Heuser, MD

Medical School Hannover
Hannover, Germany
  Connect »